Press Release

PRO-101: study design and interim results from a Phase 1 study to evaluate the safety, tolerability, PK, and PD of prosetin in ALS

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

GC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh Golipour

SonoThera Presents New Data at the 2025 MDA Conference Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery (UMD) in Treating Duchenne Muscular Dystrophy

David P. King joins Truvian’s Advisory Board

Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease

Aspen Neuroscience Advances the Automated Production of Personalized Autologous Cell Therapy for Parkinson’s Disease

Truvian Health Appoints Dr. Tina Nova to its Board of Directors

SonoThera Presents New Data at the American Society of Hematology (ASH) Annual Meeting Demonstrating the Potential of Targeted, Ultrasound-Mediated Gene Delivery to Liver